FR2828884B1 - Hydrazinopeptoides et leurs utilisations dans le traitement des cancers - Google Patents

Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Info

Publication number
FR2828884B1
FR2828884B1 FR0111120A FR0111120A FR2828884B1 FR 2828884 B1 FR2828884 B1 FR 2828884B1 FR 0111120 A FR0111120 A FR 0111120A FR 0111120 A FR0111120 A FR 0111120A FR 2828884 B1 FR2828884 B1 FR 2828884B1
Authority
FR
France
Prior art keywords
hydrazinopeptoids
cancers
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0111120A
Other languages
English (en)
French (fr)
Other versions
FR2828884A1 (fr
Inventor
Yannick Arlot Bonnemains
Karine Bouget
H Michele Baudy Floc
Grel Philippe Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Priority to FR0111120A priority Critical patent/FR2828884B1/fr
Priority to CA002430267A priority patent/CA2430267A1/fr
Priority to EP20020796313 priority patent/EP1421065A1/fr
Priority to PCT/FR2002/002935 priority patent/WO2003018557A1/fr
Priority to JP2003523221A priority patent/JP2005501121A/ja
Priority to US10/432,986 priority patent/US20040142851A1/en
Publication of FR2828884A1 publication Critical patent/FR2828884A1/fr
Application granted granted Critical
Publication of FR2828884B1 publication Critical patent/FR2828884B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/34—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
FR0111120A 2001-08-27 2001-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers Expired - Fee Related FR2828884B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0111120A FR2828884B1 (fr) 2001-08-27 2001-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
CA002430267A CA2430267A1 (fr) 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
EP20020796313 EP1421065A1 (fr) 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
PCT/FR2002/002935 WO2003018557A1 (fr) 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
JP2003523221A JP2005501121A (ja) 2001-08-27 2002-08-27 ヒドラジノペプトイドおよび癌を処置するためのそれらの使用
US10/432,986 US20040142851A1 (en) 2001-08-27 2002-08-27 Hydrazinopeptoids and their uses for treating cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0111120A FR2828884B1 (fr) 2001-08-27 2001-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Publications (2)

Publication Number Publication Date
FR2828884A1 FR2828884A1 (fr) 2003-02-28
FR2828884B1 true FR2828884B1 (fr) 2005-09-09

Family

ID=8866739

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0111120A Expired - Fee Related FR2828884B1 (fr) 2001-08-27 2001-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Country Status (6)

Country Link
US (1) US20040142851A1 (enExample)
EP (1) EP1421065A1 (enExample)
JP (1) JP2005501121A (enExample)
CA (1) CA2430267A1 (enExample)
FR (1) FR2828884B1 (enExample)
WO (1) WO2003018557A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855971B1 (fr) * 2003-06-11 2013-01-11 Centre Nat Rech Scient Analogues peptidiques comprenant au moins un residu aza-beta3-aminoacyle, et leurs utilisations, notamment en therapie
FR2859995A1 (fr) * 2003-09-23 2005-03-25 Centre Nat Rech Scient Hydrazinopeptoides reduits et leurs utilisations dans le traitement des cancers
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CA2862580A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US20190055283A1 (en) * 2016-02-29 2019-02-21 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203932A (en) * 1979-03-01 1980-05-20 Gaf Corporation Phosphoryl hydrazines
SU1613508A1 (ru) * 1988-03-28 1990-12-15 Институт Химии Ан Мсср Стабилизатор электролита железнени
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
WO1995018186A1 (en) * 1993-12-28 1995-07-06 Arqule Partners, L.P. Modular design and synthesis of aminimide containing molecules
DE19932796A1 (de) * 1999-07-14 2001-01-18 Merck Patent Gmbh Diacylhydrazinderivate

Also Published As

Publication number Publication date
CA2430267A1 (fr) 2003-03-06
JP2005501121A (ja) 2005-01-13
EP1421065A1 (fr) 2004-05-26
US20040142851A1 (en) 2004-07-22
WO2003018557A1 (fr) 2003-03-06
FR2828884A1 (fr) 2003-02-28

Similar Documents

Publication Publication Date Title
EP1370249A4 (en) NEW DENDRITIC POLYMERS AND ITS BIOMEDICAL APPLICATIONS
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
EP1392818A4 (en) FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR
EP1465854A4 (en) CHALCON DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISEASES
EP1537140A4 (en) NUCLEIC ACID SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND ASSOCIATED PROTEIN, NAME 161P2F10B
EP1453837A4 (en) TARGETED THERAPEUTICS AND ITS APPLICATIONS
EP1311262A4 (en) CANCER THERAPY THROUGH COMBINATION THERAPY
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
NO20034877L (no) Anvendelse av bifosfonater ved behandling av benmetastase forbundet med prostatakreft
IS8127A (is) Aðferðir og samsetningar sem nýta ónæmistemprandiefnasambönd í meðferð og umönnun á krabba og öðrum sjúkdómum
EP1384235A4 (en) DIFFERENTIAL PHOTOCHEMICAL AND PHOTOMECHANICAL PROCESSING
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
IL162228A (en) Shaped nanocrystal particles and methods for making the same
EP1414477A4 (en) REPEAT SEQUENCES OF THE CA125 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS
SI1599467T1 (sl) Novi cianopiridinski derivati uporabni pri zdravljenju raka in drugih motenj
NO20034430D0 (no) Tiohydantoiner og anvendelse derav for behandling av diatbetes
EP1427832A4 (en) METHYLTRANSFERASEGENE AND USES THEREOF
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60225159D1 (de) Substituierte benzimidazole und ihre anwendung in der krebsbehandlung
EP1538907A4 (en) FTSZ-HEMMER AND ITS USE
EP1512405A4 (en) COMPOSITION TO TREAT CHLOASMA AND COMPOSITION TO REDUCE MUTUAL APPEARANCE
EP1567556A4 (en) RECOMBINANT IMMUNOTOXIN AND USE IN THE TREATMENT OF TUMORS
EP1455858A4 (en) CATHETER COMPOSITION AND ITS USES
AU2003274963A8 (en) Mda-7 and free radicals in the treatment of cancer
FR2831538B1 (fr) Nouveaux derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080430